Flecainide

Cat. No.: HY-W010950

CAS No.: 54143-55-4

Molecular Formula: $C_{17}H_{20}F_6N_2O_3$

Molecular Weight: 414.34

Target: Potassium Channel; Sodium Channel

Pathway: Membrane Transporter/Ion Channel

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (241.35 mM; Need ultrasonic)

H_2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.4135 mL	12.0674 mL	24.1348 mL
5 mM	0.4827 mL	2.4135 mL	4.8270 mL
10 mM	0.2413 mL	1.2067 mL	2.4135 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.03 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na^+ current (INa) and the rapid component of the delayed rectifier K^+ current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias[1][2][3].

REFERENCES

[1]. Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8.

[2]. Aliot E, et al. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011 Feb;13(2):161-73.

[3]. Allan LD, et al. Flecainide in the treatment of fetal tachycardias. Br Heart J. 1991 Jan;65(1):46-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA